WNDM News New High-Tech Collagen Assists in Clo

FORT WORTH, Texas , Oct. 1, 2012 /PRNewswire/ -- Wound Management Technologies, Inc. (OTCQB: WNDM | WNDM.PK), a Fort Worth, Texas healthcare company, announced today their first application of their new product CellerateRX Surgical. This product was used as the primary, full-thickness incision dressing for a surgical procedure performed by orthopedic surgeon Dr. Blaine Farless at a hospital in North Texas .

(Photo: http://photos.prnewswire.com/prnh/20121001/DA83944 )

CellerateRX Surgical is a patented, hydrolyzed collagen product that is FDA cleared for surgical wounds. Other collagen products require the body to naturally break down their collagen molecules, delaying the wound healing process. CellerateRX Surgical collagen fragments are approximately 1/100 ^th the size of the native collagen molecule delivering the benefits of collagen immediately to the wound site. CellerateRX Surgical can be used alone or can safely be combined with other agents, such as antibiotics, simultaneously providing broader use by the physician. Dr. Farless said post surgery that "the incision site is the track as it's a race between healing and infection. CellerateRX Surgical helps to win that race safely and effectively in my surgical incisions."

Patients, surgeons, and hospitals are now able to benefit from a cost effective product packaged for operating room use.

Dr. Farless also commented, "After my years of experiencing positive results with CellerateRX in the clinical environment, I am excited to extend the benefit of hydrolyzed collagen to my patients undergoing surgical procedures."

New Medicare reform guidelines are forcing physicians and hospitals to re- evaluate their surgical procedure outcomes in hopes of reducing surgical wound complications. The proactive measure could negatively impact many hospitals as they will not be able to bill for wound healing complications after a surgery. CellerateRX Surgical can help improve surgical outcomes by assisting in reducing surgical wound complications in patients. The "high risk" patient having a surgical procedure can experience the utmost benefit from this product. "High risk" patients are defined as those who are obese, elderly, a smoker, diabetic, arthritic, immune compromised or those with vascular disease. These patients contribute to a disproportionate surgical wound complication rate of up to 10% nationally.